MedTrace Logo

AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

NCT04807868 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1250

Last updated 2025-03-13

No results posted yet for this study

Summary

The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liver tissue collected during standard of care liver biopsies. Paired blood/urine samples, FibroScan and relevant data will also be collected.

Conditions

  • Non-Alcoholic Fatty Liver Disease

Interventions

PROCEDURE

Standard of care liver biopsy

Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.

OTHER

Fibroscan

A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.

OTHER

Biospecimen Collection

Blood and urine will be collected.

Sponsors & Collaborators

  • BPGbio

    collaborator INDUSTRY

  • AdventHealth Translational Research Institute

    lead OTHER

Principal Investigators

  • Karen Corbin, PhD, RD · Investigator

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-22
Primary Completion
2025-12-31
Completion
2026-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04807868 on ClinicalTrials.gov